Silencing microRNA by interfering nanoparticles in mice

Su, Jie; Baigude, Huricha; McCarroll, Joshua A.; Rana, Tariq M.

doi:10.1093/nar/gkq1307

Cited by 60 publications

(58 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…129 Nanocarriers were also prepared in the form of liposomes, lipid polymers and dendrimers, which act as a vehicle for the delivery of siRNAs. 134,135 These NPs were designed in such a way that they can assemble themselves with siRNA, leading to its protection from degradation and rapid clearance from the body. Furthermore, these NPs have the capability to retain multifunctional constituents for targeted siRNA delivery and proficient infiltration into targeted cell.…”

mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,050

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,050

481

View full text Add to dashboard Cite

show abstract

“…On the contrary, nanoparticulate delivery systems (<1-μm diameter) are well suited to support a multitude of delivery-enhancing modifications. Recently, Su et al described a nanocomplex that delivers anti-miR-122 to the liver (34). Furthermore, nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) are safe, biodegradable, and have a long history of success in enhancing the delivery of therapeutic agents.…”

mentioning

confidence: 99%

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma

Babar

Cheng

Booth

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

441

378

View full text Add to dashboard Cite

is an oncogenic microRNA that regulates several pathways involved in cell division and immunoregulation. It is overexpressed in numerous cancers, is often correlated with poor prognosis, and is thus a key target for future therapies. In this work we show that overexpression of miR-155 in lymphoid tissues results in disseminated lymphoma characterized by a clonal, transplantable pre-B-cell population of neoplastic lymphocytes. Withdrawal of miR-155 in mice with established disease results in rapid regression of lymphadenopathy, in part because of apoptosis of the malignant lymphocytes, demonstrating that these tumors are dependent on miR-155 expression. We show that systemic delivery of antisense peptide nucleic acids encapsulated in unique polymer nanoparticles inhibits miR-155 and slows the growth of these "addicted" pre-B-cell tumors in vivo, suggesting a promising therapeutic option for lymphoma/leukemia. oncogene | oncomiR addiction | nanotechnology M icroRNAs (miRNAs) govern nearly every biological process investigated (1-8). in particular is one of the most salient miRNAs, and although its role in immune function has been the subject of much attention (9-14), manifold studies also implicate it in cancer pathways, particularly those of hematopoietic origin (11,(15)(16)(17)(18)(19)(20)(21). miR-155 is induced in several lymphomas, such as diffuse large B-cell lymphomas, Hodgkin lymphomas, and subsets of Burkitt lymphomas (16,18,22), and ectopic expression of miR-155 in a transgenic mouse model leads to B-cell malignancy (15, 23). Furthermore, miR-155 induction in hematopoietic cells of myeloid origin results in a myeloproliferative pathology characterized by granulocyte/ monocyte expansion in lymphoid tissues (24,25). At the molecular level, miR-155 directly targets SH2-containing inositol phosphatase (SHIP1), a negative regulator of myeloid cell proliferation and survival. Furthermore, in diffuse large B-cell lymphomas, miR-155 induction and subsequent SHIP1 repression are TNF-α-dependent (23,24,26). Although these studies provide compelling evidence for miR-155 involvement in lymphoproliferative disease, the degree to which the survival of these cancers depend on maintained miR-155 expression has not been established, a crucial point to ascertain in determining whether or not inhibition of miR-155 has therapeutic promise.It is known that several protein-coding oncogenes such as Egfr, Myc, Ras, and Her2 (among others) exhibit oncogene addiction and that tumors can become dependent on maintained expression of these genes in mouse models (27)(28)(29). Recently, we described a miR-21-induced mouse model of lymphoma in which tumors were dependent on maintained expression of miR-21, demonstrating that miRNAs are a unique class of genes that mediate oncogene addiction (30).Toward cancer therapy, anti-miR molecules could potentially be used to attenuate oncogenic miRNAs, ultimately exploiting the miRNA dependence exhibited by certain tumors. In recent years, anti-miRs have emerged as useful tools for inhibiting ...

show abstract

“…Alternatively, new techniques to re-express miRNAs with tumor suppressor roles are constantly emerging, as the administration of synthetic miRNA becomes a common therapy (TRANG et al 2010). It has also been reported the successful systemic delivery of miRNAs as anti-cancer approaches in preclinical models using liposomes viral vectors (KOTA et al 2009;RAI et al 2011) and nanoparticles (SU et al 2011). A better understanding of the molecular mechanisms of lncRNAs in cancer might lead to development of more effective cancer therapies in the near future.…”

Section: -Ncrnas In Cancer Therapymentioning

confidence: 99%

Noncoding RNA in cancer

Calvo¹

2017

PDJ

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) are diverse classes of RNA molecules not translated into proteins, which possess intricate regulatory and structural functions. NcRNAs belong to a family of regulatory transcripts that affect every stage of gene expression, from transcription and mRNA stability to mRNA translation. Recent evidence has uncovered critical roles for noncoding RNAs in cancer pathogenesis. For example, variation of specific microRNAs has shown to drive tumorigenesis in human cancer cells and mouse models. Long noncoding RNAs (lncRNAs) have also been related to diverse cancer phenotypes and neurological disorders. NcRNAs are deeply involved in the regulation of key genes that are associated with cancer, representing a promising area for new therapies. This review focuses on ncRNAs, their role in cancer, and the translational implications of noncoding RNA research that may contribute to the development of innovative therapeutic solutions to treat cancer, and improve patients' quality of life and survival.

show abstract

Silencing microRNA by interfering nanoparticles in mice

Cited by 60 publications

References 40 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma

Noncoding RNA in cancer

Contact Info

Product

Resources

About